UTv Videos

In determining the best treatment, urologist Arpeet Shah, MD, stresses the importance of thorough diagnostics.

Brooke Edwards, MD, highlights key takeaways from her LUGPA 2025 session, "Transforming your ASC."

Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape.

Martin M. Miner, MD, highlights key findings from TRAVERSE and the T4DM study.

Suzanne Merrill, MD, outlines recent progress with immunotherapy across NMIBC and MIBC.

LUGPA president Scott B. Sellinger, MD, FACS, highlights the key priorities and sessions at this year's LUGPA Annual Meeting.

Data suggest that KIM-1 is prognostic for clinical outcomes in aRCC.

Liu notes that current data—showing a response rate of just over 50%—indicate that the BCG-unresponsive CIS cohort is the most appropriate initial target population.

Bertrand Tombal, MD, PhD, shares insights from the real-world REASSURE trial.

Petros Grivas, MD, PhD, touches on the signficance of KEYNOTE-905 data, which were presented at ESMO 2025.

Monique Roobol, PhD, MSc, noted that approximately half of the 30% higher incidence of prostate cancer in the screened arm represents overdiagnosis, primarily of low-risk cancers.

Aleece Fosnight, MSPAS, PA-C, encouraged urologists to normalize the conversation by openly acknowledging that these discussions can feel embarrassing but also by celebrating patients for taking the first step.

Qian Qin, MD, outlines the background and design of the phase 2 EXPLORE-RCC trial.

Petros Grivas, MD, PhD, highlights notable trial readouts across NMIBC, MIBC, and urothelial carcinoma.

Preliminary data from the study are promising.

The key finding was that men who received rectal spacers had a 50% lower risk of biochemical failure.

Pedro C. Barata, MD, MSc, FACP, outlines ARANOTE findings stratified by age subgroups.

Hear from 5 experts as they recap some of the top data from this year's ESMO Congress.

Louise K. Kostos, MBBS, FRACP, PhD candidate, outlines initial findings from the phase 1/2 AlphaBet trial.

Beckermann explained that adenosine blockade may be better shown in the durability of response, so data collection in the study remains ongoing.

The findings revealed that patients prioritized improvements in overall survival and reductions in cancer recurrence at 5 years over all other treatment factors

Regarding the timing of sperm retrieval, the findings suggest it is reasonable and safe to delay the procedure until adulthood.

Regarding feasibility, Helo highlighted that the asynchronous format is resource-efficient.

Scott Tagawa, MD, provides an overview of key findings from the PSMAddition study, evaluating 177Lu-PSMA-617 combined with ADT and ARPI in mHSPC.

Jeremie Calais, MD, PhD, shares key findings from the phase 2 LUNAR trial, assessing the safety and efficacy of adding 177Lu-PSMA therapy before SBRT in omHSPC.

Enrique Grande, MD, shares key findings from the DISCUS trial, exploring 3 vs 6 cycles of platinum-based chemotherapy for advanced urothelial carcinoma.